L-asparaginase (ASNase) (L-asparagine amidohydrolase EC 3.5.1.1) has been widely used as a therapeutic agent in the treatment of acute lymphoblastic leukemia (ALL) and in the food industry for the removal of toxic acrylamide (formed in foods cooked at high temperatures). Accordingly, ASNase is also used in biosensors for leukemia diagnosis. To improve the performance of ASNase and overcome the limitations of free enzymes, namely low stability and biocatalytic activity, enzyme immobilization is one of the most used strategies. Several supports as carbon nanotubes, graphene and chitosan have been reported for ASNase immobilization. Among them, nanomaterials, and in particular silica, have emerged as a promising alternative support for enzyme...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
L-asparaginase (LA) is an enzyme used as a biopharmaceutical for the treatment of acute lymphoblast...
UIDP/ 50020/2020 POCI-01-0145-FEDER-031268 no. 312463/2021-9 LA/P/0006/2020 FAPESP (2018/06908-8) CE...
Since the average life expectancy is increasing, several fatal diseases usually related to aging, su...
L-asparaginase (ASNase) is an aminohydrolase enzyme used as an anticancer drug, e.g. in the treatmen...
L-asparaginase (ASNase) is an amidohydrolase that can be used as a biopharmaceutical, as an agent fo...
L-asparaginase (LA) is an antileukemic biopharmaceutical of current high-cost. LA is produced via fe...
Enzymes are widely studied biomolecules with relevant applications in several industries. Specifical...
The enzyme L-asparaginase (ASNase) presents effective antineoplastic properties for acute lymphoblas...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
L-asparaginase (ASNase, EC 3.5.1.1) is an enzyme that catalyzes the L-asparagine hydrolysis into L-a...
The enzyme L-asparaginase (ASNase) presents effective antineoplastic properties used for acute lymph...
Acute lymphoblastic leukemia (ALL) accounts with approximately 5000 new cases in the United States e...
Acute lymphoblastic leukemia (ALL) accounts with approximately 5,000 new cases in the United States ...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
L-asparaginase (LA) is an enzyme used as a biopharmaceutical for the treatment of acute lymphoblast...
UIDP/ 50020/2020 POCI-01-0145-FEDER-031268 no. 312463/2021-9 LA/P/0006/2020 FAPESP (2018/06908-8) CE...
Since the average life expectancy is increasing, several fatal diseases usually related to aging, su...
L-asparaginase (ASNase) is an aminohydrolase enzyme used as an anticancer drug, e.g. in the treatmen...
L-asparaginase (ASNase) is an amidohydrolase that can be used as a biopharmaceutical, as an agent fo...
L-asparaginase (LA) is an antileukemic biopharmaceutical of current high-cost. LA is produced via fe...
Enzymes are widely studied biomolecules with relevant applications in several industries. Specifical...
The enzyme L-asparaginase (ASNase) presents effective antineoplastic properties for acute lymphoblas...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
L-asparaginase (ASNase, EC 3.5.1.1) is an enzyme that catalyzes the L-asparagine hydrolysis into L-a...
The enzyme L-asparaginase (ASNase) presents effective antineoplastic properties used for acute lymph...
Acute lymphoblastic leukemia (ALL) accounts with approximately 5000 new cases in the United States e...
Acute lymphoblastic leukemia (ALL) accounts with approximately 5,000 new cases in the United States ...
Acute lymphoblastic leukemia (ALL) accounts with approximately 6500 new cases in the United States e...
L-asparaginase (LA) is an enzyme used as a biopharmaceutical for the treatment of acute lymphoblast...
UIDP/ 50020/2020 POCI-01-0145-FEDER-031268 no. 312463/2021-9 LA/P/0006/2020 FAPESP (2018/06908-8) CE...